Quantcast
Last updated on April 20, 2014 at 8:28 EDT

Latest Aethlon Medical Inc. Stories

2012-05-03 06:26:37

SAN DIEGO, May 3, 2012 /PRNewswire/ -- Aethlon Medical, Inc. (OTCBB: AEMD), today released the following note authored by its Chairman and CEO, Jim Joyce. (Photo: http://photos.prnewswire.com/prnh/20090325/LA88762LOGO-b) On May 19th of last year, we introduced and began marketing the Aethlon ADAPT(TM) system, a technology platform that converges the capabilities of plasma membrane technology and affinity drug mechanisms. Our Aethlon ADAPT(TM) system provides a foundation to create a...

2012-04-26 06:25:19

SAN DIEGO, April 26, 2012 /PRNewswire/ -- Aethlon Medical, Inc. (OTCBB: AEMD), today released the following note authored by its Chairman and CEO, Jim Joyce. (Photo: http://photos.prnewswire.com/prnh/20090325/LA88762LOGO-b) Our Aethlon ADAPT(TM) (Adaptive Dialysis-like Affinity Platform Technology) system converges plasma membrane technology and affinity drug agents as a basis to create novel device-based therapies that are able to target the selective removal of disease-enhancing agents...

2012-04-25 02:33:03

SAN DIEGO, April 25, 2012 /PRNewswire/ -- Aethlon Medical, Inc. (OTCBB: AEMD), today released the following note authored by its Chairman and CEO, Jim Joyce. (Photo: http://photos.prnewswire.com/prnh/20090325/LA88762LOGO-b) Aethlon Medical was originally formed to advance a medical device technology that targeted the removal of harmful metals from circulation. At the time, our strategy to treat infectious disease was a mere seed of thought and we certainly didn't envision the...

2012-04-24 06:26:09

SAN DIEGO, April 24, 2012 /PRNewswire/ -- Aethlon Medical, Inc. (OTCBB: AEMD), today released the following note authored by its Chairman and CEO, Jim Joyce. (Photo: http://photos.prnewswire.com/prnh/20090325/LA88762LOGO-b) The gold standard for determining drug therapy benefit against infectious disease targets is to measure changes in patient viral load, otherwise known as the amount of virus that is detectable in circulation. Specific to Hepatitis C virus (HCV), the best...

2012-02-07 07:15:00

SAN DIEGO, Feb. 7, 2012 /PRNewswire/ -- Aethlon Medical, Inc. (OTCBB: AEMD), the pioneer in developing selective therapeutic filtration devices to address infectious disease, cancer and other life-threatening conditions, announced today that a presentation of the Aethlon Hemopurifier® to treat Hepatitis C virus (HCV) and other infectious disease conditions will occur at the upcoming 32(nd) Annual Dialysis Conference to be held on February 26-28 at the Henry B. Gonzalez Convention...

2012-02-01 06:33:00

SAN DIEGO, Feb. 1, 2012 /PRNewswire/ -- Aethlon Medical, Inc. (OTCBB: AEMD), the pioneer in developing selective therapeutic filtration devices to address infectious disease, cancer and other life-threatening conditions, reported today that the administration of Hemopurifier® therapy during the first three days of standard of care peginterferon+ribavirin (PR) drug therapy has demonstrated both immediate and rapid virologic responses in genotype-1 infected HCV patients. An immediate...

2012-01-23 08:13:00

SAN DIEGO, Jan. 23, 2012 /PRNewswire/ -- Aethlon Medical, Inc. (OTCBB: AEMD), the pioneer in developing selective therapeutic filtration devices to address infectious disease, cancer and other life-threatening conditions, announced today that it has established an Extracorporeal Therapy Scientific Advisory Board to guide the advancement of the Aethlon Hemopurifier® and other therapies developed from the Aethlon ADAPT(TM) system. Aethlon recently established a Scientific...

2012-01-12 07:00:00

SAN DIEGO, Jan. 12, 2012 /PRNewswire/ -- Aethlon Medical, Inc. (OTCBB: AEMD), the pioneer in developing selective therapeutic filtration devices to address infectious disease, cancer and other life-threatening conditions, announced today that it has established a Sepsis & Inflammation Scientific Advisory Board to provide guidance on the development of new therapeutics, including a device to reduce the incidence of sepsis in combat-injured soldiers being advanced under a contract...

2012-01-09 13:19:00

SAN DIEGO, Jan. 9, 2012 /PRNewswire/ -- Aethlon Medical, Inc. (OTCBB: AEMD), the pioneer in developing therapeutic filtration devices to address infectious disease and cancer, announced that an audio rebroadcast of the presentation by its Chairman and CEO, James A. Joyce, at the Biotech Showcase(TM) 2012, on January 9, 2012, is now be available at: (Photo: http://photos.prnewswire.com/prnh/20090325/LA88762LOGO-b) http://www.media-server.com/m/p/dfvbu2du In addition,...

2012-01-04 12:44:00

SAN DIEGO, Jan. 4, 2012 /PRNewswire/-- Aethlon Medical, Inc. (OTCBB: AEMD), the pioneer in developing therapeutic filtration devices to address infectious disease and cancer, announced today that its Chairman and CEO James A. Joyce will be the lead-off presenter at the Biotech Showcase(TM) 2012. Mr. Joyce's presentation will begin at 9:00 am Pacific Time on January 9th, 2012. A live webcast of the presentation will be available at: http://www.media-server.com/m/p/dfvbu2du...